Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Induced Pluripotent Stem Cells01:06

Induced Pluripotent Stem Cells

6.3K
Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
6.3K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

7.4K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
7.4K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

4.3K
4.3K
Mismatch Repair01:20

Mismatch Repair

7.0K
Organisms are capable of detecting and fixing nucleotide mismatches that occur during DNA replication. This sophisticated process requires identifying the new strand and replacing the erroneous bases with correct nucleotides. Mismatch repair is coordinated by many proteins in both prokaryotes and eukaryotes.
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
7.0K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

10.1K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
10.1K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Repeated head impacts establish a senescent cranial bone marrow niche that impairs brain metabolism.

Journal of neuroinflammation·2026
Same author

Cigarette smoke induces FASN-dependent fatty acid metabolic rewiring to drive bladder cancer progression.

Cancer letters·2026
Same author

Rethinking ovarian cancer III: the past decade and future directions.

Nature reviews. Cancer·2026
Same author

Correction: BET inhibitor-based combinations targeting novel dependencies in MECOM-rearranged (r) AML.

Leukemia·2026
Same author

KRAShing pancreatic cancer before takeoff.

Science (New York, N.Y.)·2026
Same author

Overcoming menin inhibitor resistance in AML cells with combinations including BET proteins and a dual BRG1/BRM inhibitor.

Blood·2026

相关实验视频

Updated: Apr 4, 2026

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models
09:58

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models

Published on: December 9, 2016

14.5K

结合体是MYC驱动癌症的治疗漏洞

Tiffany Y-T Hsu1,2,3,4, Lukas M Simon4, Nicholas J Neill1,4

  • 1Verna &Marrs McLean Department of Biochemistry and Molecular Biology, Baylor College of Medicine, Houston, Texas 77030, USA.

Nature
|September 3, 2015
PubMed
概括
此摘要是机器生成的。

MYC的过度表达会压力结合体,这是RNA处理的关键机制. 抑制结合体可选择性地伤害MYC驱动的癌细胞,从而提供新的治疗点.

更多相关视频

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype
14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

3.7K
Using the E1A Minigene Tool to Study mRNA Splicing Changes
10:25

Using the E1A Minigene Tool to Study mRNA Splicing Changes

Published on: April 22, 2021

5.6K

相关实验视频

Last Updated: Apr 4, 2026

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models
09:58

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models

Published on: December 9, 2016

14.5K
Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype
14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

3.7K
Using the E1A Minigene Tool to Study mRNA Splicing Changes
10:25

Using the E1A Minigene Tool to Study mRNA Splicing Changes

Published on: April 22, 2021

5.6K

科学领域:

  • 癌症学
  • 分子生物学
  • 癌症遗传学

背景情况:

  • MYC (c-MYC) 是人类癌症的常见驱动因素,但仍然难以抑制治疗.
  • 致癌性MYC会增加RNA和蛋白质的合成,可能会对细胞机械造成负担.
  • 负责RNA处理的spliceosome被研究为MYC驱动癌症的潜在目标.

研究的目的:

  • 确定MYC驱动的癌症的新治疗点.
  • 研究结合体在MYC驱动的瘤发生中的作用.
  • 探索MYC和结合体组件之间的合成致死性.

主要方法:

  • 在人类乳腺上皮细胞中确定BUD31为MYC合成致命基因.
  • BUD31作为核心结合体组件的特征.
  • 在MYC过度激活下对结合体功能进行体外和体内评估.
  • 结合体组件的遗传和药物抑制.

主要成果:

  • 在MYC过度表达细胞中,它的抑制是致命的.
  • MYC过度激活会增加前体传递 RNA 的合成,从而压力结合体.
  • 在MYC过活化的细胞中,支离子体抑制会导致全球性内核保留和mRNA前成熟的缺陷.
  • 抑制结合体会影响依赖MYC的乳腺癌的存活率,瘤性和转移.

结论:

  • 瘤性MYC会对结合体产生附带压力.
  • 在MYC驱动的癌症中,spliceosome代表了一个新的治疗漏洞.
  • 针对结合体组件为治疗侵袭性MYC依赖性恶性瘤提供了一个有希望的策略.